Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema - PubMed
4 days ago
- #dupilumab
- #chronic hand eczema
- #immune signature
- Chronic hand eczema (CHE) is a complex skin condition with pain, itch, and inflammation, resembling atopic dermatitis, contact dermatitis, and psoriasis.
- A phase 2b clinical trial showed dupilumab (IL4Rα-blockade) significantly improved CHE symptoms and quality of life over 16 weeks.
- Molecular profiling revealed CHE shares immune signatures with atopic dermatitis and psoriasis, involving type 1, 2, and 3 immunity.
- Dupilumab treatment restored skin barrier and immune homeostasis in CHE patients, independent of atopic dermatitis background.
- The study suggests IL-4Rα blockade as a promising therapy for CHE, addressing mixed immune dysregulation.